Syros Pharmaceuticals, Inc. Common Stock
SYRS
SYRS was delisted on the 19th of March, 2025.
94 hedge funds and large institutions have $53.1M invested in Syros Pharmaceuticals, Inc. Common Stock in 2022 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 26 increasing their positions, 31 reducing their positions, and 11 closing their positions.
136% more call options, than puts
Call options by funds: $33K | Put options by funds: $14K
36% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 11
4% more funds holding
Funds holding: 90 → 94 (+4)
16% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 31
68% less capital invested
Capital invested by funds: $166M → $53.1M (-$113M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.46M |
| 2 |
AG
Artal Group
Luxembourg
|
+$894K |
| 3 |
Millennium Management
New York
|
+$750K |
| 4 |
Two Sigma Investments
New York
|
+$246K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$233K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$6.32M |
| 2 |
O
OrbiMed
New York
|
-$5.99M |
| 3 |
ACM
Altium Capital Management
New York
|
-$3.78M |
| 4 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$2.93M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
-$957K |
SYRS Hedge Fund Activity: Q1 2022 in Review
94 of the 6,341 institutional investors tracked by Wall St. Rank reported a position in Syros Pharmaceuticals, Inc. Common Stock (SYRS) for Q1 2022, worth a combined $53.1M — down 68% from $166M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new SYRS positions and 11 closed out — a net gain of 4 holders — while 26 added to existing stakes and 31 trimmed.
The largest buyer was Renaissance Technologies, opening a new position worth an estimated $1.46M. The largest seller was Fidelity Investments, cutting an estimated $6.32M.
- 94 institutional investors held Syros Pharmaceuticals, Inc. Common Stock (SYRS) as of Q1 2022, up from 90 in Q4 2021.
- Funds reported $53.1M of Syros Pharmaceuticals, Inc. Common Stock stock for Q1 2022, down 68% quarter-over-quarter.
- 15 funds opened new Syros Pharmaceuticals, Inc. Common Stock positions in Q1 2022 and 11 closed out, a net change of +4 holders.
- The largest Syros Pharmaceuticals, Inc. Common Stock buyer in Q1 2022 was Renaissance Technologies, an estimated $1.46M added.
- The largest Syros Pharmaceuticals, Inc. Common Stock seller in Q1 2022 was Fidelity Investments, an estimated $6.32M sold.
Based on aggregated 13F filings for Q1 2022.